Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral-treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild®. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. |
|||
|
|||
Medicine details |
|||
| Medicine name | elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®) | ||
| Formulation | 150 mg/150 mg/200 mg/245 mg film-coated tablet | ||
| Reference number | 1446 | ||
| Indication | Treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2413 | ||
| NMG meeting date | 11/09/2013 | ||
| AWMSG meeting date | 16/10/2013 | ||
| Ratification by Welsh Government | 02/12/2013 | ||
| Date of issue | 03/12/2013 | ||
| Date of last review | 01/12/2016 | ||
| Commercial arrangement | WPAS | ||